Yescarta: Clinical Trials

6 trials of Yescarta, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 6 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Active not recruiting 2, Completed 1, Not yet recruiting 1, Recruiting 1, Suspended 1
Phase 23Active not recruiting 1, Not yet recruiting 1, Suspended 1

Follow Yescarta: new trials by email Literature Review of Yescarta trials Research Report on Yescarta

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2Not yet recruitingUniversity of Michigan Rogel Cancer Center122026-11-012026-11-12
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma
Phase 1RecruitingAIDS Malignancy Consortium202025-02-132026-07-10
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Phase 1CompletedNeoImmuneTech172021-07-292026-08-10
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma
Phase 1 / Phase 2SuspendedMasonic Cancer Center, University of Minnesota302021-06-092026-11-04
Axi-cel in CNS Lymphoma
Fludarabine, Cyclophosphamide, Axicabtagene Ciloleucel - Lymphoma, Lymphoma Cns
Phase 1Active not recruitingDana-Farber Cancer Institute182020-12-042026-08-12
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
Acalabrutinib, Axicabtagene Ciloleucel - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Phase 1 / Phase 2Active not recruitingUniversity of Washington232020-12-022026-06-25

Conditions studied

Lymphoma, Large B-Cell, Diffuse (5)  ·  Lymphoma, Non-Hodgkin (2)  ·  HIV Infections (1)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Follicular (1)  ·  Recurrence (1)

Sponsors

AIDS Malignancy Consortium (1)  ·  Dana-Farber Cancer Institute (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  NeoImmuneTech (1)  ·  University of Michigan Rogel Cancer Center (1)  ·  University of Washington (1)

Countries

United States (6)

Top investigators

Ajay Gopal (1)  ·  Ariela Noy (1)  ·  Caron Jacobson, MD (1)  ·  John DiPersio, M.D. (1)  ·  Marcus Geer (1)  ·  Veronika Bachanova, MD (1)

Results publications

PMID 38022532

NIH funding

UM1CA121947 (1)